Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome

34Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aims Intramyocardial inflammation is considered an adverse prognostic factor in inflammatory cardiomyopathy (CMi). However, the precise nature of immune system factors relevant for the prediction of long-term course remains elusive. The aim of this study was to analyse the prognostic relevance of perforin in a large cohort of patients with CMi. Methods and results We investigated 495 consecutive patients with suspected CMi, undergoing endomyocardial biopsies (EMBs), and examined haemodynamic measurements after a long follow-up period (interquartile range 10.2-37.1-months). In EMBs, myocardial inflammation was assessed by histology and immunohistology. At follow-up, 388 patients (Group I) showed stable mild dysfunction or significant improvement, with LVEF rising from 46.2-±-14.8% to 64.3-±-12.3% (P-

Cite

CITATION STYLE

APA

Escher, F., Kühl, U., Lassner, D., Stroux, A., Westermann, D., Skurk, C., … Schultheiss, H. P. (2014). Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome. European Journal of Heart Failure, 16(10), 1066–1072. https://doi.org/10.1002/ejhf.148

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free